SCHEMBL7554809

SCHEMBL7554809

CCC(CC1CC1)Nc1nc(C)nc2c1c1ccccc1n2-c1c(C)cc(C)cc1C

nearest known ligand 0.56

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
CRHR1 P34998 17/20 0.56
ADORA3 P0DMS8 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7557846 0.87 CRHR1 (0.52) CRHR1
SCHEMBL7684145 0.83 CRHR1 (0.54) CRHR1
SCHEMBL7677447 0.83 CRHR1 (0.53) CRHR1
SCHEMBL7557048 0.82 CRHR1 (0.52) CRHR1
SCHEMBL7560074 0.81 CRHR1 (0.53) CRHR1
SCHEMBL7681407 0.80 CRHR1 (0.54) CRHR1
SCHEMBL7684260 0.79 CRHR1 (0.48) CRHR1
SCHEMBL7676298 0.78 CRHR1 (0.48) CRHR1
SCHEMBL7788921 0.78 CRHR1 (0.49) CRHR1
SCHEMBL8178987 0.76 CRHR1 (0.56) CRHR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020019406-A1 9H-pyrimido[4,5-b]indole derivatives: CRF1 specific ligands NEUROGEN CORPORATION 2002-02-14 US claimed
US-20020019406-A1 9H-pyrimido[4,5-b]indole derivatives: CRF1 specific ligands NEUROGEN CORPORATION 2002-02-14 US disclosed
US-6284766-B1 DIAGNOSIS, THERAPY OF STRESS DISORDERS NEUROGEN CORPORATION 2001-09-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020019406-A1 9H-pyrimido[4,5-b]indole derivatives: CRF1 specific ligands HTR1D, CRHR1, HTR1A CRHR1 2/4885ADORA3 159/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.